Onglyza expands European licence

pharmafile | March 4, 2011 | News story | Sales and Marketing |  AZ, AstraZeneca, BMS, Bristol-Myers Squibb, Onglyza, diabetes, renal impairment, saxagliptin, type II diabetes 

European regulators have approved a licence extension for diabetes treatment Onglyza, making it the first drug in its class that can also treat moderate or severe renal impairment.

It is estimated that more than 25% of patients with type II diabetes have moderate or severe renal impairment and doctors will now have the option of prescribing Onglyza, but only at half its normal 5mg dose.

They will also need to assess their patients’ renal function prior to treatment commencing and, in keeping with routine care, regularly monitor them after treatment begins.

The companies further note that “as experience in patients with severe renal impairment is very limited, [Onglyza] should be used with caution in this population and is not recommended for patients with end-stage renal failure”.

Advertisement

Patients with mild renal impairment will be able to take a full 5mg dose of Onglyza (saxagliptin).

The drug is co-promoted by AstraZeneca and Bristol-Myers Squibb and currently indicated to help type II diabetics keep their sugar levels low.

Ben Adams

Related Content

Study to examine ways of improving diabetes care for younger adults

Researchers at Northumbria University are leading a ÂŁ1.3m study aimed at helping GP practices improve …

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

The Gateway to Local Adoption Series

Latest content